Revance Therapeutics, Inc. Files Form 4 with the SEC

Revance Therapeutics, Inc. (Issuer) has filed a Form 4 with the Securities and Exchange Commission (SEC) on behalf of one of its executives, indicating changes in their ownership of company stock. Form 4 is a document required to be filed with the SEC whenever there are changes in the holdings of company insiders, such as directors, officers, or shareholders with more than 10% of the company’s stock. This filing is crucial for transparency and to ensure that investors are aware of any insider trading activities that may impact the company’s stock price.

Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic products for the treatment of various skin conditions. The company is known for its proprietary neuromodulator product, DaxibotulinumtoxinA, which is used in both aesthetic and therapeutic applications. With a commitment to advancing the field of dermatology and providing patients with cutting-edge solutions, Revance Therapeutics, Inc. continues to make strides in the biopharmaceutical industry.

For more information about Revance Therapeutics, Inc. and its innovative products, you can visit their official website here.